Abstracts & posters
Abstract submission is closedBMUC 2021
Save the date for this virtual meeting! (Registration and programme online soon!)
More info >
Abstracts & posters
Abstract submission is closed. All abstracts have been reviewed by the BMUC board and posters can be consulted here below.
Best poster contest
During BMUC 2020 Light, you could vote for the 4th winner of the poster contest. The winner will be announced during the best poster session from 11:30-11:45 on Saturday 3 October 2020.
Winning abstracts
Congratulations to the 3 winners of the poster contest!
These winners will receive a price of 1.500 euro – 1.000 euro and 750 euro, kindly offered by
 |
Kim Van der Eecken | Ghent University Hospital, Ghent, Belgium | Tracking the origins of metastatic seeding in de novo metastatic prostate cancer |
 |
Romain Diamand | Erasme Hospital, Brussels, Belgium | External Validation of the Briganti Nomogram Predicting Lymph Node Invasion in Patients with Intermediate and High-risk Prostate Cancer Diagnosed with Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study |
 |
Wout Devlies | University Hospitals Leuven, Leuven, Belgium | Longitudinal analysis of urinary- and erectile function after RALP in high- versus low/intermediate-risk prostate cancer in a large prospective database |
Research grant
Congratulations to the research grant winner!
This winner will receive a price of 10.000 euro, kindly offer by
 |
Anita Thomas | University Hospitals Leuven | Establishment of a cell-derived penile cancer xenograft in a humanized mouse |
Posters
You can consult the posters of the submitted abstracts for BMUC 2020 here below.
1. Radical prostatectomy for de novo low-volume metastatic prostate cancer
Sarah Buelens, Ghent University Hospital, Ghent, Belgium
2. Cost-utility analysis of metastasis-directed therapy in the treatment of oligometastatic prostate cancer
Elise De Bleser, Ghent University Hospital, Ghent, Belgium
3. ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer
Bram De Laere, Karolinska Institutet, Stockholm, Sweden
4. Longitudinal analysis of urinary- and erectile function after RALP in high- versus low/intermediate-risk prostate cancer in a large prospective database
Wout Devlies, University Hospitals Leuven, Leuven, Belgium
5. Survival after RALP: influence of pre- and perioperative patient, cancer and surgeon-specific parameters
Wout Devlies, University Hospitals Leuven, Leuven, Belgium
6. Unravelling the proteomic landscape of urinary extracellular vesicles in prostate cancer
Bert Dhondt, Ghent University Hospital, Ghent, Belgium
8. Impact of modern imaging tools on management of prostate cancer, a single center evaluation
Guillaume Grisay, Jolimont Hospital, Haine Saint-Paul, Belgium
9. Changes in serum PSA after Holmium Laser Enucleation of the Prostate (HoLEP) are predictive for the future diagnosis of prostate cancer
Edward Lambert, OLV Hospital, Aalst, Belgium
10. Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review
Elke Rammant, Ghent University Hospital, Ghent, Belgium
11. Predictors for Perioperative Complications in Cytoreductive Nephrectomy: Results from an International Multicenter Collaboration
Eduard Roussel, University Hospitals Leuven, Leuven, Belgium
12. Tracking the origins of metastatic seeding in de novo metastatic prostate cancer
Kim Van der Eecken, Ghent University Hospital, Ghent, Belgium
13. Inferring the genomic landscape of lymph-node positive high-risk prostate cancer
Jan Vanwelkenhuyzen, University Ghent, Ghent, Belgium
14. Haptoglobin blood-based biomarker for prognosis in mRCC patients – an interim analysis
Tijl Vermassen, Ghent University Hospital, Ghent, Belgium